Treatment strategies for nonmotor manifestations of Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 5, 2009, Pages 773-784

  Reichmann, Heinz ^a   Ziemssen, Tjalf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Autonomic nervous system; Dementia; Depression; Nonmotor features; Olfaction; Pain; Parkinson's disease

Indexed keywords

AMITRIPTYLINE; ATROPINE; BOTULINUM TOXIN; CITALOPRAM; DESIPRAMINE; DESMOPRESSIN; DOMPERIDONE; DONEPEZIL; ESCITALOPRAM; FLUDROCORTISONE; FLUOXETINE; GALANTAMINE; IPRATROPIUM BROMIDE; LEVODOPA; METOCLOPRAMIDE; MIDODRINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PIRENZEPINE; PLACEBO; PRAMIPEXOLE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SERTRALINE; TACRINE; THREO 3,4 DIHYDROXYPHENYLSERINE; UNINDEXED DRUG; YOHIMBINE;

ADD ON THERAPY; ALZHEIMER DISEASE; ANHEDONIA; APRAXIA; AUTONOMIC DYSFUNCTION; BLEPHAROSPASM; BRADYKINESIA; BRAIN DEPTH STIMULATION; CHEESE; CHEWING GUM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROCONVULSIVE THERAPY; ERECTILE DYSFUNCTION; FATIGUE; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPOTENSION; LOW DRUG DOSE; MAGNETIC STIMULATION; MAJOR DEPRESSION; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PAIN; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; TREATMENT DURATION; TREATMENT WITHDRAWAL; TREMOR; UNSPECIFIED SIDE EFFECT; UROGENITAL SYSTEM; VISUAL IMPAIRMENT; VOMITING;

ANIMALS; COGNITION DISORDERS; DISEASE MANAGEMENT; HUMANS; HYPOTENSION, ORTHOSTATIC; PAIN; PARKINSON DISEASE; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 67649588370     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902811605     Document Type: Review

References (113)

1. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study. Neurology 1993;42:1142-1146 (Pubitemid 33596372)
2. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely and Jones; 1817
3. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312
4. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72 •• This study shows convincingly Lewy bodies in autonomic structures of the gastrointestinal tract. (Pubitemid 43233790)
5. Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249(Suppl 3):III/1-5
6. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196-1202 • This study underlines that patients with hyposmia may be prone to become PD patients. (Pubitemid 39429962)
7. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181 (Pubitemid 39037913)
8. Haehner A, Hummel T, Hummel C, et al. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007;22:839-842 (Pubitemid 46800106)
9. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl):S2-7 (Pubitemid 47444539)
10. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2007;13:323-332 (Pubitemid 47212791)
11. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008;15(Suppl 1):14-20
12. Doty RL, Stern MB, Pfeiffer C, et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:138-142 • This is one of the earliest papers which underline that hyposmia is a frequent finding in PD.
13. Müller A, Müngersdorf M, Reichmann H, et al. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002;9:521-524
14. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50:34-41 (Pubitemid 32591460)
15. Hummel T, Jahnke U, Sommer U, et al. Olfactory function in patients with idiopathic Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm 2005;112:669-676 (Pubitemid 40591199)
16. Büttner T, Kuhn W, Müller T, et al. Distorted color discrimination in 'de novo' parkinsonian patients. Neurology 1995;45:386-387
17. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's disease with dementia (GEPAD). J Neurol 2008;255:255-264
18. Aarsland D, Tandberg E, Larssen JP, Cummings JL. Frequency of dementia in Parkinson's disease. Arch Neurol 1996;53:538-542
19. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392 (Pubitemid 36314364)
20. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237 (Pubitemid 37443310)
21. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707 (Pubitemid 47597592)
22. McKeith IG. Consensus guidelinesfor the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB International Workshop. J Alzheimers Dis 2006;9(3 Suppl):417-423 (Pubitemid 44253336)
23. Jellinger KA. Post-mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm 1999;56(Suppl):1-29
24. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411 (Pubitemid 30078073)
25. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324-325 (Pubitemid 26293733)
26. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712 (Pubitemid 34557010)
27. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939 (Pubitemid 40909549)
28. Müller T, Welnic J, Fuchs H, et al. The DONPAD study-treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl 2006;71:27-30
29. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8 (Pubitemid 38180686)
30. Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007;8:1011-1023 (Pubitemid 351232608)
31. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2005;351:2509-2518
32. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-461
33. Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other non-motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf 2008;31:79-94
34. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-941 (Pubitemid 37294855)
35. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinatons in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907 (Pubitemid 44848936)
36. Edwards K, Royal D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 2007;23:401-405 (Pubitemid 46897177)
37. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036 (Pubitemid 32009817)
38. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Pschiatry 2005;20:938-944 (Pubitemid 43055105)
39. Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry 2007;22:890-895 (Pubitemid 47455272)
40. Fukunishi I, Hosokawa K, Ozaki S. Depression antedating the onset of Parkinson's disease. JPN J Psychiatry Neurol 1991;45:7-11
41. Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson's disease. J Neurol 2004;251(Suppl 6):VI/24-7 (Pubitemid 39371684)
42. Schuurman AG, van den Akker M, Ensinck KT, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002;58:1501-5104 (Pubitemid 34552956)
43. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-454
44. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002;17:445-454 (Pubitemid 36040955)
45. Funkiewicz A, Ardouin C, Caputo E, et al. Long-term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:834-839 (Pubitemid 38658504)
46. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease. A community based study. Arch Neurol 1996;53:175-179
47. Dooneief G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49:305-307
48. Poewe WH. Die Neuropsychologie der Parkinson-Krankheit. In: Stern GM, Madeja UD, Poewe WH (Hrsg). Trends in Diagnostik und Therapie des Morbus Parkinson. Berlin: de Gruyter, 1993. p. 43-49
49. Heinz A, Schmidt LG, Reischies FM. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients-neurobiological correlates. Pharmacopsychiatry 1994;27(Suppl 1):7-10 (Pubitemid 24260105)
50. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092 (Pubitemid 47067217)
51. Koerts J, Leenders KL, Koning M, et al. The assessment of depression in Parkinson's disease. Eur J Neurol 2008;15:487-492
52. Andersen J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-Dopa. Acta Neurol Scand 1980;62:210-219
53. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55:1216-1218 (Pubitemid 30803005)
54. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15:986-989
55. Wermuth L, Soerensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial. Nord J Psychiatry 1998;52:163-171 (Pubitemid 28310706)
56. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003;18:552-554 (Pubitemid 36763664)
57. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-857
58. Weintraub D, Taraborelli D, Morales KH, et al. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 2006;18:377-383
59. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 2006;21:1119-1122 (Pubitemid 44336595)
60. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65 (Pubitemid 30228411)
61. Reichmann H, Brecht MH, Koster J, et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 2003;17:965-973 (Pubitemid 37410070)
62. Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006;248:266-270 • This paper nicely illustrates that the dopamine agonist pramipexole is able to improve depression and anhedonia in PD. (Pubitemid 44754866)
63. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-607 (Pubitemid 43876990)
64. Perugi C, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34:137-141 (Pubitemid 32701763)
65. Culpepper L, Lovalick LJ. A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry 2008;10:25-30 (Pubitemid 351879938)
66. Giménez-Roldán S, Dobato JL, Mateo D. Treatment of depression in Parkinson's disease with moclobemide: a pilot open-label study. Parkinsonism Relat Disord 1997;3:219-225 (Pubitemid 28188834)
67. Epstein CM, Evatt ML, Funk A, et al. An open sutdy of repetitive magnetic stimulation in treatment-resistant depression with Parkinson's disease. Clin Neurophyisol 2007;118:2189-2194 (Pubitemid 47386041)
68. da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008 [Epub ahead of print]
69. Moellentine C, Rummens T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998;10:187-193 (Pubitemid 28241366)
70. Martigononi E, Pacchetti C, Godi L, et al. Autonomic disorders in Parkinson's disease. J Neural Transm 1995;45(Suppl):11-19
71. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2007;13:323-332 (Pubitemid 47212791)
72. Wolters E, Braak H. Parkinson's disease:premotor clinico-pathological correlations. J Neural Transm 2006;70(Suppl):309-319
73. Alcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1470-1471 (Pubitemid 39279820)
74. Pursiainen V, Korpelainen TJ, Haapaniemi HT, et al. Selegiline and blood pressure in patients with Parkinson's disease. Acta Neurol Scand 2007;115:104-108 (Pubitemid 46018545)
75. Jancovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38-48 (Pubitemid 23205925)
76. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randominzed, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046-1051
77. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001;18:495-505 (Pubitemid 32664724)
78. Stemper B, Bedric A, Welsch G, et al. Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 2006;67:1781-1785 (Pubitemid 44900753)
79. Eady MJ, Tyrer JH. Alimentary disorder in parkinsonism. Aust Ann Med 1965;14:13-22
80. Chou KL, Evatt M, Hinson V, Kompoliti K. Sialrrhoea in Parkinson's disease: a review. Mov Disord 2007;22:2306-2313
81. Sheffield JK, Jankovic J. Botolinum toxin in the treatment of tremor, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother 2007;7:637-647 (Pubitemid 46911613)
82. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002;17:1318-1320 (Pubitemid 36041348)
83. Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007;22:2268-2273
84. Postma AG, Heesters M, van Laar T. Radiotherapy of the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord 2007;22:2430-2435 (Pubitemid 351155992)
85. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurology 2003;2:107-116 (Pubitemid 37443331)
86. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2008;103:1049
87. Abbott RD, Petrovich H, White LH, et al. Frequency of bowel movements and future risk of Parkinson's disease. Neurology 2001;57:456-462 (Pubitemid 32757593)
88. Jost W. Autonome Regulationsstörungen beim Parkinson-Syndrom. Shaker Verlag, Aachen 1999
89. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007;15:1239-1244
90. Fowler CJ. Urinary disorders in Parkinson's disease and multiple system atrophy. Funct Neurol 2001;16:277-282 (Pubitemid 33149806)
91. Barrero R, Mir P, Cayuela A, et al. Urinary symptoms and urodynamic findings in Parkinson's disease. Neurologia 2007;22:93-98 (Pubitemid 46570330)
92. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-374 (Pubitemid 32772536)
93. Mano Y, Nakamuro T, Takayanagi T, Mayer RF. Sweat function in Parkinson's disease. J Neurol 1994;241:573-576 (Pubitemid 24309913)
94. Schmidt C, Herting B, Prieur S, et al. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord 2007;22:2123-2126
95. Nègre-Pagès L, Regragui W, Bouhassira D, et al. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008 [Epub] • The best study on pain in PD so far.
96. Scherder E, Wolters E, Polman C, et al. Pain in Parkinson's disease and multiple sclerosis: ist relation to the medial and lateral pain systems. Neurosci Biobehav Rev 2005;29:1047-1056 (Pubitemid 41242779)
97. Sage JI. Pain in Parkinson's disease. Curr Treat Options Neurol 2004;6:191-200 (Pubitemid 38915123)
98. Ford B. Pain in Parkinson's disease. Clin Neurosci 1998;5:63-72 (Pubitemid 128751580)
99. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005;20:1557-1563
100. Drake DF, Harkins S, Qutubuddin A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 2005;20:335-341 (Pubitemid 43030023)
101. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895-899 (Pubitemid 28517665)
102. Iranzo A, Santamariá J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005;26:247-252 (Pubitemid 41022369)
103. Schenck CH, Bundlie SR, Patterson AL, Mahowald MW. Rapid eye movement sleep behavior disorders. A treatable parasomnia affecting older adults. JAMA 1987;257:1786-1789
104. Stacy M. Sleep disorders in Parkinson's disease: epidemiology and management. Drugs Aging 2002;19:733-739 (Pubitemid 35305832)
105. Frucht S, Rogers JD, greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910
106. Factor SA, McAlamey T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;5:280-285 (Pubitemid 20373607)
107. Ondo WG, Fayle R, Atassi F, Jancovic J. Modafinil for daytime somnolence in Parkinson's disease: double-blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639 (Pubitemid 41697625)
108. Miyasaki JM, Al Hassan K, Lang AE, Voon V. Punding prevalence in Parkinson's disease. Mov Disord 2007;22:1179-1181 (Pubitemid 47067232)
109. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-423 (Pubitemid 36975988)
110. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66:1750-1752 (Pubitemid 43964638)
111. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002;17:1371-1374 (Pubitemid 36041360)
112. Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson's disease. J Neurol Sci 2008;266:216-228 (Pubitemid 351186509)
113. Giocannoni G, O'sallican JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428 (Pubitemid 30248740)